approv sooner expect fda throw
announc regulatori clearanc factori calibr cgm
system regulatori approv clearanc expect posit
howev note fda inconsist put mildli baffl
key question remain would yield increas sensor util
would caus step-up patient add unclear stage bump
pt keep rate
fda chang goalpost replac claim libr lack
thereof guardian connect notabl
clear via de-novo class ii categori essenti make
predic devic other look get clearanc via process
special control de novo applic unknown surpris
natur process indic fda shift stanc
factory-calibr wear auto-shutoff cgm use
stand-alone integr cgm hybrid close loop system assum
asp would rang pda would requir new
custom ce mark expect later year launch
numer question remain auto-shutoff
would play field remind number patient
field stretch util would impact
inventori ensu upgrad process would
undertak would medicar roll-out especi given
final importantli key question remain would
increment top-lin gain upgrad would factori calibr
necessarili caus step-up increment patient gain would sensor
util take step-up given auto-shutoff featur math indic
everyth remain step util alon would yield
increment annual top-lin gain without chang
assumpt patient add use model chang rais pt
howev calcul factor real impact abbott
stand-alon side also remain unclear opex
margin profil chang launch extent
increas util npv stori increas
real question continu struggl remain impact
abbott recent field check indic patient likabl
abbott lack alarm one biggest knock
libr abbott continu make strong inroad side
segment far see strong uptak also compound
disrupt sale rep side abbott
statement oper
number mm
good
prdt dev
sg
page
leader stand-alone continu glucos monitor system
risk achiev price target
libr gain reimburs cgm
libr gain greater share new patient
suraj kalia certifi view express report accur reflect person view
subject compani secur part compens directli
indirectli relat specif recommend view express report
